Cargando…

Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery

Overactive bladder (OAB) symptoms increase with age and involve several comorbidities. OnabotulinumtoxinA (BoNT-A) intravesical injection is a treatment choice for patients who are intolerant of or refractory to antimuscarinics. However, the increased risk of urinary tract infection and elevated pos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Chun-Hou, Wang, Chung-Cheng, Jiang, Yuan-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848618/ https://www.ncbi.nlm.nih.gov/pubmed/27023603 http://dx.doi.org/10.3390/toxins8040091

Ejemplares similares

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
por: Hsiao, Sheng-Mou, et al.
Publicado: (2016)

Are we underestimating urinary retention following intravesical onabotulinumtoxinA in women with overactive bladder and a history of prior pelvic surgery?
por: Holmes, Angela, et al.
Publicado: (2022)

Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
por: Hoag, Nathan, et al.
Publicado: (2016)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder
por: Jiang, Yuan-Hong, et al.
Publicado: (2014)

Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder
por: Hsiao, Sheng-Mou, et al.
Publicado: (2017)

Bleeding risk in female patients undergoing intravesical injection of onabotulinumtoxinA for overactive bladder: a Danish retrospective cohort study
por: El Issaoui, Meryam, et al.
Publicado: (2023)

Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder
por: DiCarlo‐Meacham, Angela M., et al.
Publicado: (2022)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

A Feasibility Study to Evaluate Changes in Urinary Metabolites after OnabotulinumtoxinA Injection for Refractory Overactive Bladder
por: Tellechea, Laura M., et al.
Publicado: (2022)

Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction
por: Jhang, Jia-Fong, et al.
Publicado: (2018)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder
por: Nekkanti, Silpa, et al.
Publicado: (2017)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty
por: El-Azab, Ahmed S., et al.
Publicado: (2013)

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility
por: Wang, Chung-Cheng, et al.
Publicado: (2016)

Intravesical Loss of OnabotulinumtoxinA During Endoscopic Intradetrusor Injection - A Multicenter Experience
por: Šámal, Vladimír, et al.
Publicado: (2020)

Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T‐cell leukemia virus type 1‐associated myelopathy: A single‐institution case series
por: Matsuo, Tomohiro, et al.
Publicado: (2021)

Effect of Bladder Injection of OnabotulinumtoxinA on the Central Expression of Genes Associated with the Control of the Lower Urinary Tract: A Study in Normal Rats
por: Markopoulou, Soultana, et al.
Publicado: (2022)

Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
por: Ethans, KD, et al.
Publicado: (2014)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
por: Shabir, Habiba, et al.
Publicado: (2021)

300 IU vs. 200 IU of OnabotulinumtoxinA for detrusor overactivity
por: Persu, Cristian
Publicado: (2014)

Trigonal-Sparing vs. Trigonal-Involved OnabotulinumtoxinA Injection for the Treatment of Overactive Bladder: A Systematic Review and Meta-Analysis
por: Cui, Yuanshan, et al.
Publicado: (2021)

OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice
por: Hamid, Rizwan, et al.
Publicado: (2020)

Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study
por: El-Dakhakhny, Amr S., et al.
Publicado: (2019)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
por: Zhang, Rui, et al.
Publicado: (2015)

The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder
por: Dmochowski, Roger, et al.
Publicado: (2023)

Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)
por: Wang, Chung-Cheng, et al.
Publicado: (2021)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

Retrospective Observational Study of Treatment Patterns and Efficacy of onabotulinumtoxinA Therapy in Patients with Refractory Overactive Bladder in Clinical Practice
por: Ko, Kwang Jin, et al.
Publicado: (2023)

Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity
por: Leitner, Lorenz, et al.
Publicado: (2016)

Protocol for a prospective magnetic resonance imaging study on supraspinal lower urinary tract control in healthy subjects and spinal cord injury patients undergoing intradetrusor onabotulinumtoxinA injections for treating neurogenic detrusor overactivity
por: Leitner, Lorenz, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective
por: Hamid, Rizwan, et al.
Publicado: (2014)

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia
por: Sastre Real, María, et al.
Publicado: (2020)

Treatment of Non-neurogenic Overactive Bladder with OnabotulinumtoxinA: Systematic Review and Meta-analysis of Prospective, Randomized, Placebo-controlled Clinical Trials
por: Arruda, Raquel Martins, et al.
Publicado: (2018)

Erratum to: OnabotulinumtoxinA is Effective in Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity Regardless of Concomitant Anticholinergic Use or Neurologic Etiology
por: Ginsberg, David, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6bqf8oev84tu9qceek2daghs6q